Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society
This consensus reviewed the main current issues of clinical application and integration into everyday practice of a new targeted preventive therapy for migraine using monoclonal antibodies (mAbs) to the calcitonin gene related peptide (CGRP) ligand or receptor. These recommendations are based on cur...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-10-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1900 |
| _version_ | 1827062737507713024 |
|---|---|
| author | A. V. Sergeev G. R. Tabeeva E. G. Filatova A. V. Amelin L. R. Akhmadeeva E. R. Lebedeva V. V. Osipova Yu. E. Azimova N. V. Latysheva O. B. Doronina K. V. Skorobogatykh |
| author_facet | A. V. Sergeev G. R. Tabeeva E. G. Filatova A. V. Amelin L. R. Akhmadeeva E. R. Lebedeva V. V. Osipova Yu. E. Azimova N. V. Latysheva O. B. Doronina K. V. Skorobogatykh |
| author_sort | A. V. Sergeev |
| collection | DOAJ |
| description | This consensus reviewed the main current issues of clinical application and integration into everyday practice of a new targeted preventive therapy for migraine using monoclonal antibodies (mAbs) to the calcitonin gene related peptide (CGRP) ligand or receptor. These recommendations are based on current scientific and clinical studies and an analysis of the results of several years of clinical use. The main purpose of the consensus is to assist practitioners in prescribing effective prophylactic treatment of migraine using anti-CGRP mAbs and to improve care for patients with various forms of the disease. |
| first_indexed | 2024-04-10T02:01:13Z |
| format | Article |
| id | doaj.art-aed33d42913549629b5ada854bc02631 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2025-02-18T20:01:37Z |
| publishDate | 2022-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-aed33d42913549629b5ada854bc026312024-10-17T16:15:30ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422022-10-0114510911610.14412/2074-2711-2022-5-109-1161315Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research SocietyA. V. Sergeev0G. R. Tabeeva1E. G. Filatova2A. V. Amelin3L. R. Akhmadeeva4E. R. Lebedeva5V. V. Osipova6Yu. E. Azimova7N. V. Latysheva8O. B. Doronina9K. V. Skorobogatykh10I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaAcad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaBashkir State Medical University, Ministry of Health of RussiaUral State Medical University, Ministry of Health of Russia; International Headache Treatment Center “Europe-Asia”Z.P. Solovyev Research and Practical Psychoneurology Center, Moscow Healthcare DepartmentOOO “University Headache Clinic”; Research Institute of General Pathology and PathophysiologyI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaNovosibirsk State Medical University, Ministry of Health of RussiaOOO “University Headache Clinic”This consensus reviewed the main current issues of clinical application and integration into everyday practice of a new targeted preventive therapy for migraine using monoclonal antibodies (mAbs) to the calcitonin gene related peptide (CGRP) ligand or receptor. These recommendations are based on current scientific and clinical studies and an analysis of the results of several years of clinical use. The main purpose of the consensus is to assist practitioners in prescribing effective prophylactic treatment of migraine using anti-CGRP mAbs and to improve care for patients with various forms of the disease.https://nnp.ima-press.net/nnp/article/view/1900migrainemonoclonal antibodiescalcitonin gene-related peptideconsensus |
| spellingShingle | A. V. Sergeev G. R. Tabeeva E. G. Filatova A. V. Amelin L. R. Akhmadeeva E. R. Lebedeva V. V. Osipova Yu. E. Azimova N. V. Latysheva O. B. Doronina K. V. Skorobogatykh Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society Неврология, нейропсихиатрия, психосоматика migraine monoclonal antibodies calcitonin gene-related peptide consensus |
| title | Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society |
| title_full | Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society |
| title_fullStr | Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society |
| title_full_unstemmed | Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society |
| title_short | Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society |
| title_sort | application of a new biological pathogenetic therapy of migraine in clinical practice expert consensus of the russian headache research society |
| topic | migraine monoclonal antibodies calcitonin gene-related peptide consensus |
| url | https://nnp.ima-press.net/nnp/article/view/1900 |
| work_keys_str_mv | AT avsergeev applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT grtabeeva applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT egfilatova applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT avamelin applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT lrakhmadeeva applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT erlebedeva applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT vvosipova applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT yueazimova applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT nvlatysheva applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT obdoronina applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety AT kvskorobogatykh applicationofanewbiologicalpathogenetictherapyofmigraineinclinicalpracticeexpertconsensusoftherussianheadacheresearchsociety |